Safety & Efficacy of Alosetron


Click here to start

Table of Contents

Safety & Efficacy of Alosetron


Study Design (S3BA3001/S3BA3002)

Primary Endpoint

“In the Past Seven Days Have You Had Adequate Relief of Your Irritable Bowel Syndrome Pain and Discomfort?”

“Have You Felt or Experienced a Sense of Urgency Today?”

“Please Enter the Number of Times You Have Passed Stool Today”

“Please Rate the Consistency Of Your Stool Today”

Efficacy Update

International Comparator

In the past seven days have you had adequate relief of your irritable bowel syndrome pain and discomfort? (Diarrhea-Predominant)


IBS Global Improvement Question

Global Improvement Responder

Efficacy Conclusion


Agreements With FDA Prior To June 27, 2000

2 Databases (June 1, 2000)


Constipation (Phase II/III)

Constipation (Phase III) Management


Constipation - Clinical Trials (Hospitalized)

Constipation - Spontaneous Reports (Hospitalized)

Constipation Conclusion

Ischemic Colitis

Ischemic Colitis - Clinical Trials

Ischemic Colitis - Spontaneous (June 1, 2000)

Chronic Colitis

Ischemic Colitis

Ischemic Colitis Conclusion

Hepatic Function

ALT (ɯx Normal)

Alkaline Phosphatase/ Bilirubin

Elevated Liver Enzymes

Hepatic Function Conclusions

“Other” Serious Events (21 Total - 11 Reviewed) (130,000 Prescriptions)

Overall Conclusion

Overall Conclusion (continued)

Author: stj11454